Phase IIa data support S-600918 as promising option for refractory chronic cough Sep. 30, 2019 No Comments
Gala Therapeutics gets breakthrough device designation for Rheox system Sep. 17, 2019 By Liz Hollis No Comments Chronic bronchitis affects more than 9 million people in the U.S., but current treatments fail to address the overproduction of mucus. Gala Therapeutics Inc., of Menlo Park, Calif., is looking to change that.Read More
New protein-arginine deiminase type-4 inhibitors synthesized at Nanjing TransThera Biosciences Sep. 13, 2019 No Comments
Theravance reports first-in-human data on TD-8236 for inflammatory lung disease Sep. 9, 2019 No Comments
Vicore completes phase I study of angiotensin II type 2 receptor agonist C-21 Sep. 9, 2019 No Comments
RSS